1228 — Canbridge Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Annual income statement for Canbridge Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	12	31.2	79	103	85.1
Cost of Revenue
Gross Profit	6.88	18.8	48.9	64.2	54.3
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	854	1,105	556	473	519
Operating Profit	-842	-1,074	-477	-370	-434
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-846	-1,077	-483	-379	-443
Provision for Income Taxes
Net Income After Taxes	-846	-1,077	-483	-379	-443
Net Income Before Extraordinary Items
Net Income	-846	-1,077	-483	-379	-443
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-846	-1,077	-483	-379	-443
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.98	-2.49	-1.14	-0.893	-0.85